BELLA TRIP-P: Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics

Sponsor
University of Washington (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05566431
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (NIH)
428
9
2
45.7
47.6
1

Study Details

Study Description

Brief Summary

Narrative:

Worldwide, traumatic brain injury (TBI) is a leading cause of death and disability among children and adolescents. The Investigators aim to test whether pediatric TBI treatment guided by invasive intracranial pressure monitoring produces better patient outcomes than care guided by a protocol without invasive monitoring. Study findings will inform clinical practice in treating pediatric severe TBI globally. Focused didactic and experience-based learning opportunities will increase the research capacity of pediatric intensivists in Latin America.

Condition or Disease Intervention/Treatment Phase
  • Other: ICP
  • Other: CREVICE
N/A

Detailed Description

Abstract:

Children who survive severe traumatic brain injury (sTBI) live with profound impairments that alter their development and future possibilities. Worldwide, TBI is the leading cause of death and disability for children/ adolescents with the US annual incidence 6 times greater than MS, HIV/AIDS, spinal cord injury, and breast cancer combined.

Our primary focus for scientific investigation is to conduct a high quality randomized controlled trial addressing a critical TBI management question: Does using a protocol with information from intracranial pressure (ICP) monitoring to direct treatment of children with sTBI improve outcomes vs an aggressive management protocol based on imaging and clinical examination alone? This follows on our adult ICP study which found no outcome differences and has occasioned re-thinking of treatment guidelines for sTBI patients >13. A separate study is essential because children are not simply small adults and some treatment approaches carry age-related additional risks. Thus, study findings will inform US and global clinical practice.

This trial will be conducted in 8 Latin American pediatric ICUs where infrastructures and practice patterns are optimal for strong internal validity and resources represent trauma care in the developing world. The successful adolescent/adult BEST TRIP trial, which collected high-quality data in similar environments (cited > 900 times) underscores the feasibility of this approach.

Specific Aim: In a Phase III randomized superiority trial in 428 children with sTBI from 8 Latin American pediatric trauma centers, test the effect on outcomes of management of sTBI guided by a protocol using information from ICP monitors vs. management using a protocol that uses imaging and clinical exams to guide treatment.

Hypothesis #1: Children with severe TBI whose acute care treatment is managed using a protocol based on data from ICP monitoring will have significantly lower mortality and better quality of life and global outcome at 6 months post-trauma than those whose treatment is managed with a protocol based on imaging and clinical exam. The primary measure of functional recovery is the PedsQL at 6 months. A secondary measure is GOSE-Peds.

Hypothesis #2: Incorporating ICP monitoring into sTBI patient care will minimize secondary complications, decrease length of stay in ICU and decrease brain-specific treatments.

Specific Aim: The Investigators will train personnel in centers new to research how to conduct high-quality scientific studies, and will extend the training for the personnel with whom the Investigators have been working, solidifying previous capacity-building efforts, and initiating new efforts.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
428 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
In a Phase III multicenter, parallel-group, randomized superiority trial in 428 children with sTBI from 7 Latin American pediatric trauma centers, the objective is to test the efficacy of the treatment protocol from the Guidelines based on ICP monitoring among children with sTBI in improving global outcome measured by Pediatric Quality of Life Inventory (PedsQL) 6 mos after injury compared to treatment based on a non-invasive imaging & clinical examination (CREVICE) protocol specifically modified for a pediatric population.In a Phase III multicenter, parallel-group, randomized superiority trial in 428 children with sTBI from 7 Latin American pediatric trauma centers, the objective is to test the efficacy of the treatment protocol from the Guidelines based on ICP monitoring among children with sTBI in improving global outcome measured by Pediatric Quality of Life Inventory (PedsQL) 6 mos after injury compared to treatment based on a non-invasive imaging & clinical examination (CREVICE) protocol specifically modified for a pediatric population.
Masking:
Single (Outcomes Assessor)
Masking Description:
Outcome assessors will not go into the ICU when a study participant is being treated, unmasked study staff will not inform the outcome assessor which protocol was used for a participant. and outcome assessors will remind participant's parents to refrain for telling them which treatment protocol was used for the participant.
Primary Purpose:
Treatment
Official Title:
Pediatric Severe Traumatic Brain Injury in Latin America - A Randomized Trial Comparing Two Management Protocols
Anticipated Study Start Date :
Oct 10, 2022
Anticipated Primary Completion Date :
Jul 31, 2026
Anticipated Study Completion Date :
Jul 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: ICP monitoring based Protocol

Arm one will use a consensus-developed management protocol for paediatric severe traumatic brain injury based on recommendations from the Brain Trauma Foundation Guidelines, which uses invasive intracranial pressure monitoring

Other: ICP
The intervention is a management protocol that includes ICP monitoring for children with severe traumatic brain injury
Other Names:
  • Intracranial-pressure-monitoring-based management protocol
  • Active Comparator: No ICP Monitoring Protocol CREVICE

    Arm two will use the Consensus-Revised Imaging and Clinical Examination (CREVICE) management protocol for paediatric severe traumatic brain injury based on imaging and clinical examination in the absence of invasive intracranial pressure monitoring

    Other: CREVICE
    The intervention is a management protocol that is based on imaging and clinical examinations without ICP monitoring for children with severe traumatic brain injury
    Other Names:
  • Imaging-and-clinical-examination-based management protocol
  • Outcome Measures

    Primary Outcome Measures

    1. Pediatric Quality of Life Inventory (PedsQL) [6 months after injury]

      PedsQL is a generic, health-related quality of life instrument developed to measure the core dimensions of physical, cognitive, mental, social health, and role (school) function. Minimum and maximum values: 0-100. Higher scores have better outcomes.

    Secondary Outcome Measures

    1. Pediatric Quality of Life Inventory (PedsQL) [3 months after injury]

      PedsQL is a generic, health-related quality of life instrument developed to measure the core dimensions of physical, cognitive, mental, social health, and role (school) function. Minimum and maximum values: 0 - 100. Higher the score means a better outcome.

    2. Glasgow Outcome Scale - Extended (GOS-E) Pediatric [3 and 6 months after injury]

      GOS-E is the most common measure of functional outcome in adult TBI trials. Its pediatric version is the primary outcome in the NINDS-funded ADAPT study. Minimum and maximum values: 1-8. Higher score has worse outcomes.

    3. Mortality [3 and 6 months]

      Percent of participants who have died by the assessment time.

    4. Brain-specific interventions [1 month average]

      Total number of individual interventions directed at treating measured or suspected intracranial hypertension (i.e., brain-specific treatment) per hour summed over the duration of brain-specific treatment in ICU. Time Frame for brain-specific treatments is through acute hospitalization, an average of one (1) month and for GOS-E Peds is conducted 3 and 6 months after injury.

    5. ICU length of stay [1 month average]

      ICU length of stay related to TBI management is through acute hospitalization and for an average of one (1) month.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Year to 12 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Provision of signed and dated informed consent form by the parent(s) or guardian(s)

    2. Non-penetrating TBI

    3. Admission to study hospital within 24 hours of injury

    4. Total GCS score ≤ 8 on admission or within first 48 hours after injury (measured using pediatric GCS 1 for children < 2 years old and standard GCS for older children)

    5. Age 1 through 12 years

    6. Able to randomize:

    • Within 24 hours of injury (for patients with GCS ≤ 8 on admission) OR

    • Within 24 hours of deterioration (for patients deteriorating to GCS ≤ 8 within 48 hours of injury)

    Exclusion Criteria:
    1. Motor GCS score of 6

    2. GCS of 3 with bilaterally fixed and dilated pupils

    3. Injury thought to be intentionally inflicted by a family member or caregiver.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Washington, Harborview Medical Center Seattle Washington United States 98104
    2 Hospital de Niños Benjamín Bloom San Salvador El Salvador
    3 Hospital Regional de Esquintla Escuintla Guatemala
    4 Hospital General San Juan de Dios Guatemala City Guatemala
    5 Hospital Regional de Occidente San Juan de Dios Quetzaltenango Guatemala
    6 Hospital Escuela Tegucigalpa Honduras
    7 Hospital de Emergencias Pediátricas Lima Peru
    8 Hospital Edgardo Rebagliati Martins Lima Peru
    9 Instituto Nacional de Salud del Niño - San Borja Lima Peru

    Sponsors and Collaborators

    • University of Washington
    • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    Investigators

    • Principal Investigator: Randall Chesnut, MD, University of Washington

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Randall M. Chesnut, Professor, School of Medicine, University of Washington
    ClinicalTrials.gov Identifier:
    NCT05566431
    Other Study ID Numbers:
    • STUDY00013122
    • 1R01HD106273-01
    First Posted:
    Oct 4, 2022
    Last Update Posted:
    Oct 4, 2022
    Last Verified:
    Oct 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Randall M. Chesnut, Professor, School of Medicine, University of Washington
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 4, 2022